Phase I Safety Study of Stereotactic Radiosurgery With Concurrent and Adjuvant PD-1 Antibody Nivolumab in Subjects With Recurrent or Advanced Chordoma
Phase of Trial: Phase I
Latest Information Update: 15 Oct 2017
At a glance
- Drugs Nivolumab (Primary)
- Indications Germ cell and embryonal neoplasms
- Focus Adverse reactions
- 19 Apr 2017 Planned primary completion date changed from 1 Jan 2020 to 1 Mar 2020.
- 19 Apr 2017 Status changed from not yet recruiting to recruiting.
- 14 Dec 2016 New trial record